MedTrace Logo

IL-11 in the Development of Multiple Sclerosis

NCT03735823 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 96

Last updated 2022-06-06

No results posted yet for this study

Summary

Since the last submission, the investigator have further characterized the potential of IL--11 to induce encephalitogenic CD4+IL--17A+, IL--21+ and GM--CSF+ cells, which upon passive transfer induced severe RREAE with IL--17A+CCR6+ CD4+ cell, neutrophil, CD8+ and B--cell accumulation within the CNS (manuscript submitted for publication). These findings confirmed our hypothesis and further characterization of the IL--11--induced encephalitogenic CD4+ cells will be performed as planned in the grant proposal

Conditions

Interventions

OTHER

No intervention, just collect blood samples and CSF samples

No intervention

Sponsors & Collaborators

  • Thomas Jefferson University

    lead OTHER

Principal Investigators

  • Silva Markovic-Plese, MD PhD · Thomas Jefferson University

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2023-05-31
Completion
2023-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03735823 on ClinicalTrials.gov